HerriotTabuteauMD

Publications

U.S. Patents

Dr. Tabuteau is the inventor on more than 290 issued U.S. patents. These patents may be viewed on the U.S. Patent and Trademark Office (USPTO) website by clicking here.

Select Scientific Publications and Presentations

  1. Tabuteau H, Jones A, Anderson A, Jacobson M, Iosifescu DV. Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. Am J Psychiatry. 2022 May 18.
  2. Iosifescu DV, Jones A, O’Gorman C, Streicher C, Feliz S, Fava M, Tabuteau H. Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI). J Clin Psychiatry. 2022 May 30;83(4).
  3. O’Gorman C, Jones A, Iosifescu DV, Thomas Z, Tabuteau H. Rapid Effects of AXS-05, an Oral NMDA Receptor Antagonist, in Major Depressive Disorder: Results From Two Randomized, Double-Blind, Controlled Trials. Biological Psychiatry. 2021;89:S244.
  4. Jones A, O’Gorman C, Anderson A, Tabuteau H. Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist, in the Prevention of Relapse in Patients With Treatment-Resistant Depression: Results From MERIT, a Double-Blind, Placebo-Controlled Relapse Prevention Trial. Neuropsychopharmacology. 2021;46(SUPPL 1):201-201.
  5. O’Gorman C, Jones A, Anderson A, Jacobson M, Feliz S, Streicher C, Thomas Z, Tabuteau H. Rapid Antidepressant Effects and MADRS Core Symptom Improvements With AXS-05, an Oral NMDA Receptor Antagonist, in Major Depressive Disorder: Results From Two Randomized, Double-Blind, Controlled Trials. Neuropsychopharmacology.2021;46(SUPPL 1):201-202.
  6. O’Gorman C, Jones A, Cummings JL, Tabuteau H. Efficacy and safety of AXS‐05, a novel, oral, NMDA‐receptor antagonist with multimodal activity, in agitation associated with Alzheimer’s disease: Results from ADVANCE‐1, a phase 2/3, double‐blind, active and placebo‐controlled trial: Developments in clinical trials and cognitive assessment. Alzheimer’s & Dementia. 2020; 16(e047684).
  7. A Jones, R McIntyre, M Jacobson, C Streicher, Z Thomas, H Tabuteau. Impact of AXS-05, an Oral NMDA Receptor Antagonist, on Anhedonic Symptoms in Major Depressive Disorder. American Society of Clinical Psychopharmacology (ASCP), June 2022.
  8. A Jones, C Streicher, Z Thomas, H Tabuteau. Improvement in Anxiety Symptoms in Depressed Patients Treated with AXS-05 (Dextromethorphan Bupropion): Results from the EVOLVE Open label, Long term Study. American Society of Clinical Psychopharmacology (ASCP), June 2022.
  9. A Jones, C Streicher, Z Thomas, H Tabuteau. AXS-05 (Dextromethorphan Bupropion) Improves Depressive Symptoms and Functioning in Patients with One Prior Treatment Failure: Results from the EVOLVE Long Term, Open Label Study. American Society of Clinical Psychopharmacology (ASCP), June 2022.
  10. A Jones, C O’Gorman, C Streicher, S. Feliz, D Iosifescu, H Tabuteau. Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results From the GEMINI Trial. American Psychiatric Association (APA), May 2021.
  11. A Jones, C O’Gorman, H Tabuteau. Sustained Effects of AXS-05, an Oral NMDA Receptor Antagonist, in Treatment Resistant Depression Patients: Results from the COMET-TRD Trial. American Society of Clinical Psychopharmacology (ASCP), June 2021.
  12. C O’Gorman, A Jones, D Iosifescu, H Tabuteau. Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results from the GEMINI Phase 3, Double-Blind, Placebo-Controlled Trial (Oral Presentation). American Society of Clinical Psychopharmacology (ASCP), May 2020.
  13. A Anderson, D Iosifescu, M Jacobson, A Jones, K Kennon, C O’Gorman, S Stahl, H Tabuteau. Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results of a Phase 2, Double-Blind, Active-Controlled Trial. ASCP. Scottsdale, AZ. May 28-31, 2019.
  14. C O’Gorman, A Jones, J Cummings, H Tabuteau. Efficacy and Safety of AXS-05, a Novel Oral NMDA Receptor Antagonist with Multimodal Activity, in the Treatment of Alzheimer’s Disease Agitation: Results of the ADVANCE-1 Trial (Oral Presentation). Clinical Trials on Alzheimer’s Disease (CTAD), November 2020.
  15. C O’Gorman, D Iosifescu, A Jones, K Kennon, R Niecestro, G Papakostas, H Tabuteau. Clinical Development of AXS-05 for Treatment Resistant Depression and Agitation Associated with Alzheimer’s Disease.  American Psychiatric Association (APA) May 2018.
  16. Z Thomas, R Lipton, A Jones, A Chhabra, S Alter, H Tabuteau. Identifying Areas of Unmet Need among Migraineurs with Inadequate Response to Acute Therapies: Results from the MOMENTUM trial. American Headache Society (AHS) June 2022.
  17. Jones A, Tepper SJ, Thomas Z, Tabuteau H. Efficacy of AXS-07 (MoSEIC (TM) meloxicam and rizatriptan) in patients with risk factors for inadequate response to acute migraine medications. Headache 2022;62:142-143.
  18. A Jones, C O’Gorman, S Tepper, H Tabuteau. Efficacy and Safety of AXS-07(MoSEIC™ Meloxicam/Rizatriptan) in the Acute Treatment of Migraine: Results from the INTERCEPT Phase 3 Trial. American Headache Society (AHS) June 2021.
  19. A Jones, C O’Gorman, R Lipton, S Tepper, H Tabuteau. Efficacy and Safety of AXS-07 for the Acute Treatment of Migraine: Results from the MOMENTUM (Maximizing Outcomes in Treating Acute Migraine) Phase 3 Randomized, Double-blind, Active- and Placebo-controlled Study. American Academy of Neurology (AAN) Science Highlights platform, September 2020.
  20. O’Gorman C, Jones A, Tepper SJ, Askew C, Lipton RB, Tabuteau H. Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the Acute Treatment of Migraine: Results from the MOMENTUM Phase 3, Randomized, Double-blind, Active- and Placebo controlled Trial. The Journal of Headache and Pain. 2021; 22(Suppl 1):AL055.
  21. Jones A, O’Gorman C, Askew C, Tabuteau H. Long Term Efficacy and Safety of AXS-07 (MoSEIC (TM) Meloxicam-Rizatriptan) for the Acute Treatment of Migraine: Results from the MOVEMENT Phase 3 Trial. Annals of Neurology. 2021;90:S134-S134.
  22. Jones A, O’Gorman C, Tepper SJ, Lipton RB, Tabuteau H. Efficacy and Safety of AXS-07 (MoSEIC Meloxicam/Rizatriptan) in the Acute Treatment of Migraine: Results from the INTERCEPT Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Annals of Neurology. 2020;88: S150-S151.
  23. O’Gorman C, Jones A, Thorpy MJ, Tabuteau H. Efficacy and Safety of AXS-12 in the Treatment of Narcolepsy: Results from a Phase 2, Double-Blind, Placebo-Controlled, Crossover Trial. Sleep. 2020; 43(Supplement_1):A281-A281.
  24. C O’Gorman, A Jones, A Chhabra, M Thorpy, H Tabuteau. Efficacy and Safety of AXS-12 in the treatment of Narcolepsy: Results from a Phase 2, Double-Blind, Placebo-Controlled, Crossover Trial. Meeting of the Associated Professional Sleep Societies (SLEEP), August 2020.
Scroll to top